Share on StockTwits

Genomic Health (NASDAQ:GHDX) EVP Steven Shak sold 7,000 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $27.00, for a total transaction of $189,000.00. Following the transaction, the executive vice president now directly owns 312,298 shares in the company, valued at approximately $8,432,046. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Genomic Health (NASDAQ:GHDX) traded up 3.15% during mid-day trading on Thursday, hitting $28.12. 75,202 shares of the company’s stock traded hands. Genomic Health has a one year low of $23.90 and a one year high of $37.24. The stock’s 50-day moving average is $26.93 and its 200-day moving average is $27.81. The company’s market cap is $878.5 million.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The company had revenue of $67.00 million for the quarter, compared to the consensus estimate of $68.47 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.91 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on GHDX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note on Thursday. They now have a $29.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genomic Health in a research note on Wednesday, May 7th. They now have a $28.00 price target on the stock, down previously from $29.00. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Genomic Health currently has an average rating of “Hold” and a consensus target price of $29.38.

Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.